In the 1980s and early 1990s, Dr. Barrie Carter served as the chief of the Laboratory of Molecular and Cellular Biology in the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health. During that time, his group performed seminal work in adeno-associated virus (AAV) type 2 (AAV2) biology, including creating one of the first infectious clones of AAV2 and some of the first packaged AAV2 vectors. This work contributed substantially to the development of AAVs as gene therapy vectors. Part of the success of the group was due to Dr. Carter's ability to attract and manage a diverse team of talented individuals who synergized into a collaborative group that was more than the sum of its parts. This review describes some of the promising practices employed by the Carter group, which allowed such a diverse group to function so well. These practices included promoting a culture of co-mentoring, open communication, and respectful questioning.

中文翻译：

---

NIH 的卡特实验室：生物医学研究中的包容性卓越模型。

在 1980 年代和 1990 年代初期，Barrie Carter 博士担任美国国立卫生研究院糖尿病、消化和肾脏疾病研究所分子和细胞生物学实验室主任。在此期间，他的团队在腺相关病毒 (AAV) 2 型 (AAV2) 生物学方面进行了开创性工作，包括创建了第一个 AAV2 感染性克隆和一些第一个包装的 AAV2 载体。这项工作极大地促进了 AAV 作为基因治疗载体的发展。该小组的成功部分归功于 Carter 博士能够吸引和管理多元化的才华横溢的团队，这些人才协同作用成为一个协作小组，而不仅仅是各部分的总和。这篇综述描述了卡特小组采用的一些有前途的做法，这使得如此多样化的群体能够如此出色地运作。这些做法包括促进共同指导、公开沟通和尊重提问的文化。